Israel Biotech Fund (IBF)

Israel Biotech Fund, IBF for short, is a specialized life sciences investor based in Rehovot that allocates exclusively to drug development and therapeutic assets. The fund is supported by a network of pharmaceutical advisors, which gives portfolio companies access to senior commercial and clinical experience that is hard to replicate at a generalist VC. Healthcare AI founders should be clear-eyed: this is a therapeutics shop, not a software shop, and a fit only exists if the AI is genuinely embedded in drug discovery, target identification, or clinical development.

Stages range from Series A to Series C, with check sizes between $5 million and $25 million. Sub-verticals are pharma and biotech. The record does not list named portfolio companies in the data set used here, but the fund’s positioning suggests asset-centric deals rather than platform-only software bets.

Approach IBF only with a therapeutic asset or a platform that produces clear drug candidates with mechanism-of-action data. Pure clinical decision support, hospital workflow, or non-drug diagnostic AI products will not fit. Israeli incorporation is helpful but not strictly required given the fund’s global pharma network. Founders should come prepared with preclinical data, IP positioning, and a target product profile rather than software KPIs, and should plan to syndicate with at least one strategic pharma partner over the life of the company.